Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

A groundbreaking study has compared the three top weight loss medications on the market, which has produced some surprising ...

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...

Are weight-loss drugs the medical innovation the insurance industry has been waiting for? Could they reshape claims experience across mortality, ...

A new oral medication, Orforglipron, is set to revolutionize weight loss and diabetes management, offering a pill alternative ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...